Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy

Aliment Pharmacol Ther. 2005 Apr 1;21(7):841-9. doi: 10.1111/j.1365-2036.2005.02410.x.

Abstract

Background: Long-term effect of YMDD mutations on liver histology in Chinese hepatitis B patients is unknown.

Aim: To examine the effect of prolonged lamivudine treatment on liver histology in Chinese patients with and without YMDD mutations.

Methods: Liver histology was assessed in 85 patients on long-term lamivudine at baseline and year 1, and at year 3 for 25 patients.

Results: Comparing patients with and without YMDD mutations at year 1, the former had higher baseline median necroinflammatory (11 vs. six respectively, P = 0.014) and fibrosis scores (three vs. one respectively, P = 0.001). The proportion of patients with improvement in necroinflammation and worsening of fibrosis was comparable for patients with and without YMDD mutations at year 1 (57.1%, 14.3% vs. 55%, 15% respectively) and year 3 (57.9%, 26.3% vs. 50%, 16.7% respectively). Comparing the histology at year 1 and 3, more patients with YMDD mutations developing after year 1 had worsening of necroinflammation than patients with persistent YMDD wild type (53.8% vs. 25% respectively).

Conclusions: Patients who developed YMDD mutations had higher baseline histological scores. With YMDD mutations, the liver histology became less favourable after 3 years than at the first year, although there was still improvement when compared with that at baseline.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Asian People / genetics*
  • Biopsy / methods
  • China / ethnology
  • DNA, Viral / genetics
  • Female
  • Hepatitis B virus / genetics
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / ethnology
  • Hepatitis B, Chronic / pathology
  • Humans
  • Lamivudine / therapeutic use*
  • Liver / pathology*
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / virology
  • Male
  • Middle Aged
  • Mutation / genetics
  • Reverse Transcriptase Inhibitors / therapeutic use*

Substances

  • DNA, Viral
  • Reverse Transcriptase Inhibitors
  • Lamivudine